Estrogen Hypersensitivity Vulvitis: 11 Case Insights
Rare chronic cyclic vulvovaginitis from endogenous or exogenous oestrogen allergy, affecting premenopausal women.
Oestrogen Hypersensitivity Vulvitis
Oestrogen hypersensitivity vulvitis is a rarely reported form of chronic cyclic vulvovaginitis due to endogenous or exogenous oestrogen allergy.
Who gets oestrogen hypersensitivity vulvitis (demographics)
Oestrogen hypersensitivity vulvitis has been reported in a very small number of cases, primarily affecting premenopausal women aged 11–48 years, with a mean age of onset around 26 years. Most patients have prior exposure to exogenous hormones, such as the oral contraceptive pill, though not all. The majority have never been pregnant at diagnosis. Rarely, postmenopausal women aged 47–63 years on hormone replacement therapy (HRT) develop constant symptoms rather than cyclic ones.
This condition predominantly affects women of reproductive age due to fluctuating endogenous oestrogen levels during menstrual cycles. Case series document 11 patients, including nine with cyclic vulvitis and two with HRT-induced symptoms, highlighting its rarity but specificity in hormone-sensitive individuals.
Causes
Oestrogen hypersensitivity vulvitis is localised to the vulva, likely due to the high sensitivity of genital oestrogen receptors. It is considered a dose-dependent type IV hypersensitivity reaction, involving delayed T-cell mediated immune responses to oestrogen. Intradermal testing in affected patients showed positive delayed-type hypersensitivity to endogenous oestrogens, with some also reacting to progesterone.
In premenopausal cases, endogenous oestrogen surges during the luteal phase of the menstrual cycle trigger symptoms. Exogenous oestrogen from HRT or oral contraceptives can provoke similar reactions in susceptible individuals. Unlike irritant or infectious vulvitis, this is an allergic phenomenon confirmed by skin testing negative in healthy controls and those with other vulvar dermatoses.
- Endogenous oestrogen: Natural hormonal fluctuations in menstrual cycles.
- Exogenous oestrogen: From HRT or contraceptives.
- Mechanism: Type IV hypersensitivity localised to vulval tissues.
Clinical features
Symptoms follow a strict cyclic pattern aligned with the menstrual cycle, worsening 3–10 days before menstruation and resolving shortly after onset. Key features include intense vulval itch, redness, swelling, and irritation, often with minimal or no vaginal discharge. The vulva appears oedematous, erythematous, and may have a glazed or shiny surface due to chronic rubbing or scratching.
In HRT-related cases, symptoms are constant rather than cyclic, emerging soon after starting therapy. Severity can lead to sleep disturbance, dyspareunia (painful intercourse), and significant quality-of-life impairment. Physical signs are confined to the vulva, sparing the vagina in most cases, distinguishing it from broader vaginitis.
| Symptom | Description | Timing |
|---|---|---|
| Vulval itch | Severe, burning pruritus | Luteal phase (premenstrual) |
| Redness and swelling | Erythema, oedema | Cyclic flares |
| Irritation | Soreness, excoriations | During flares |
| Vaginal discharge | Minimal or absent | N/A |
Complications
Chronicity leads to secondary changes such as lichenification (skin thickening), fissuring, and post-inflammatory hyperpigmentation from repeated scratching. Emotional distress, anxiety, and depression are common due to intractable symptoms unresponsive to standard therapies. Rarely, severe cases may result in vulval scarring or sexual dysfunction. In children or adolescents, it can impact psychosocial development if undiagnosed.
Untreated, symptoms persist until menopause, when oestrogen levels naturally decline. HRT cases resolve upon discontinuation, avoiding long-term complications.
Diagnosis
Oestrogen hypersensitivity vulvovaginitis is a clinical diagnosis based on the cyclic pattern of symptoms and failure to respond to standard treatments for vulval itch. Essential steps include:
- Detailed history: Confirm cyclic premenstrual flares, prior hormone exposure, nulliparity.
- Examination: Vulval erythema/oedema without discharge or infection signs.
- Swabs: Negative for candida, bacteria, herpes.
- Patch/intradermal testing: Positive delayed reaction to oestrogen (research setting).
Controls in studies showed no reactions, supporting specificity. Vulval biopsy may show non-specific inflammation but is not diagnostic.
Differential diagnoses
Several conditions mimic cyclic vulvitis:
- Candidiasis: Responds to antifungals; positive swabs.
- Lichen simplex chronicus: Itch-scratch cycle without cyclicity.
- Vulval psoriasis/eczema: Wider skin involvement.
- Atrophic vaginitis: Postmenopausal, low oestrogen but not hypersensitivity.
- Contact dermatitis: To irritants/soaps, non-cyclic.
Failure to respond to antifungals, steroids, or emollients points to oestrogen hypersensitivity.
Treatment
Treatment targets oestrogen reduction or antagonism, as standard therapies fail.
- Oestrogen suppression: Progestin-only pill, depo-provera, or GnRH analogues to lower levels. Three of nine cyclic cases responded.
- Oestrogen antagonists: Tamoxifen or clomiphene (off-label).
- HRT cases: Immediate cessation leads to resolution.
- Symptomatic: Potent topical corticosteroid (e.g., clobetasol) for flare control; one case succeeded long-term.
- Supportive: Emollients, avoid irritants, cotton underwear.
Surgery (oophorectomy) is reserved for refractory cases. One patient recovered at menopause.
Outcome
Cyclic cases persist until menopause, when symptoms resolve due to oestrogen decline. HRT-related vulvitis resolves upon stopping therapy. Four of eleven patients elected no treatment, managing with avoidance. Early recognition prevents chronic morbidity.
Frequently Asked Questions
What is oestrogen hypersensitivity vulvitis?
A rare allergy to oestrogen causing cyclic vulval inflammation in premenopausal women.
Who is at risk?
Premenopausal women (11–48 years) with hormone exposure history; rarely postmenopausal on HRT.
How is it diagnosed?
By cyclic symptoms unresponsive to standard therapy; confirmed by oestrogen skin testing.
What does it look like?
Red, swollen, itchy vulva premenstrually; minimal discharge.
How is it treated?
Oestrogen suppression (progestins, GnRH), antagonists, or HRT cessation.
Does it go away?
Yes, at menopause for cyclic cases; immediately off HRT.
References
- Vulvitis attributed to hypersensitivity to estrogen. A report of 11 cases — Fischer G, Ayer B, Frankum B, Spurrett B. J Reprod Med. 2000-06-01. https://pubmed.ncbi.nlm.nih.gov/10900584/
- Oestrogen hypersensitivity vulvitis — DermNet NZ. Accessed 2026. https://dermnetnz.org/topics/oestrogen-hypersensitivity-vulvitis
- Vaginitis (Vulvovaginitis) — University of Utah Health. Accessed 2026. https://healthcare.utah.edu/womens-health/gynecology/vaginitis
- Vulvitis: Causes, symptoms, and treatment — Medical News Today. Accessed 2026. https://www.medicalnewstoday.com/articles/318834
- Vulvitis (Vulvar Itching): Causes, Symptoms & Treatment — Cleveland Clinic. Accessed 2026. https://my.clevelandclinic.org/health/diseases/15175-vulvitis
Similar Articles
Read full bio of medha deb
